awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q28472098-05D1B0BD-F3D2-45E4-ABBF-F62CC818200B
Q28472098-05D1B0BD-F3D2-45E4-ABBF-F62CC818200B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28472098-05D1B0BD-F3D2-45E4-ABBF-F62CC818200B
A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example
P2860
Q28472098-05D1B0BD-F3D2-45E4-ABBF-F62CC818200B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28472098-05D1B0BD-F3D2-45E4-ABBF-F62CC818200B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5b6f70f60848bece43bba590cfd07c37755c677e
P2860
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.